Basal media required for growth of Endothelial cells, Phenol Red Free, 500 mL (supplements and growth factors sold separately)
Culture system containing EBMTM Basal Medium (CC-3121) and EGMTM Endothelial Cell Growth Medium SingleQuotsTM Supplements (CC-4133) required for growth of endothelial cells. (Pack of 6)
Culture system containing EBMTM-2 Basal Medium (CC-3156) and EGMTM-2 MV Microvascular Endothelial Cell Growth Medium SingleQuotsTM supplements (CC-4147) required for growth of Microvascular Endothelial Cells (Pack of 6)
This product has been discontinued. The suggested alternative is EGMTM-2 MV Microvascular Endothelial Cell Growth Medium-2 BulletKitTTM (Catalog # CC-3202) and/or its components.
This product has been discontinued. The suggested alternative is EGMTM-2 MV Microvascular Endothelial Cell Growth Medium-2 BulletKitTM (Cat. # CC-3202) and/or its components.
Culture system containing EBMTM-2 Basal Medium (CC-3156) and EGMTM-2 SingleQuotsTM Supplements (CC-4176) required for growth of Endothelial Cells. Available for immediate shipment.
This product has been discontinued. The suggested alternative is EGMTM-2 MV Microvascular Endothelial Cell Growth Medium-2 BulletKitTTM (Catalog # CC-3202) and/or its components.
Culture system containing SABMTM Basal Medium and SAGMTM SingleQuotsTM supplements required for growth of Small Airway Epithelial cells
D-SAEC-COPD, Small Airway Epithelial Cells from donors with COPD
-
Natural Killer Cells InfographicNatural Killer cells have an innate ability to recognize and destroy non-self cells.
-
3D Natural Killer Cell-mediated Cytotoxicity AssayLonza White Paper
-
3D Natural Killer (NK) Cell-mediated Cytotoxicity (CMC) Assay
-
Natural Killer (NK) Cell Expansion, Activation and Cytotoxicity AssayProtocol instructions
-
Therapeutic Approaches to Enhance Natural Killer Cell Cytotoxicity: The Force AwakensPoster published by Nature Reviews Drug Discovery, sponsored by Lonza. Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches. The poster shows the approaches to NK cell tumor targeting.
-
Transfection Protocol for Human NK Cells - Nucleofector™ I/II/2b Device SeriesInstructions of use for transfection of human natural killer cells with Nucleofector™ 1/2 Devices (incl. 1, 2b, 2N, 2S)
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cellsA strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells.
-
NK Cell Assay using 3D Bioprinted Tumor ModelsThis white paper describes an ex vivo assay for NK cell killing activity in a 3D bioprinted cervical cancer tumor model.
-
TechSheet - Poietics™ Human Immune System CellsTechnical Product Information Sheet
-
CAR T cells in Cancer TherapyA poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.